Clinical Trials - CGTX

NCT IDTitleStatusPhasesStart DateCompletion DatePrimary Completion Date
NCT05531656A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's DiseaseACTIVE_NOT_RECRUITINGPHASE22023-06-282027-042027-04
NCT05893537Study to Evaluate the Efficacy and Safety of Oral CT1812 in Participants With Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (AMD).TERMINATEDPHASE22023-06-162025-03-282025-03-04
NCT05225415Study to Evaluate the Safety, Tolerability and Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy BodiesCOMPLETEDPHASE22022-05-192024-11-252024-11-25
NCT05248672Study to Assess the Pharmacokinetics of CT1812 in Older Healthy VolunteersCOMPLETEDPHASE12022-02-152022-06-012022-06-01
NCT05225389Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of CT1812 in Healthy Adult Male SubjectsCOMPLETEDPHASE12021-12-312022-01-242022-01-17
NCT04735536Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEGCOMPLETEDPHASE22020-07-092023-04-262023-04-26
NCT03507790A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.COMPLETEDPHASE22018-10-102024-05-292024-05-29
NCT03522129Study to Evaluate the Effect of CT1812 Treatment on Amyloid Beta Oligomer Displacement Into CSF in Subjects With Mild to Moderate Alzheimer's DiseaseCOMPLETEDPHASE12018-05-302019-02-062019-02-06
NCT03493282Effect of CT1812 Treatment on Brain Synaptic DensityCOMPLETEDPHASE1, PHASE22018-03-282020-10-162020-10-16
NCT03716427Drug Interaction Study of CT1812 in Healthy VolunteersCOMPLETEDPHASE12016-11-102017-02-152016-12-27
NCT02907567Clinical Trial of CT1812 in Mild to Moderate Alzheimer's DiseaseCOMPLETEDPHASE1, PHASE22016-092017-092017-08-24
NCT02570997Ascending Dose Study of CT1812 in Healthy VolunteersCOMPLETEDPHASE12015-092016-05
NCT00529581A Study of C105 on Cognitive Dysfunction in Persons With Multiple SclerosisCOMPLETEDPHASE22006-112008-042008-03